BioVie(NASDAQ) BIVIW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-29%
5 YearN/A
1 Year-31%
1 Month-29%
$0.25
-13.76%
-0.04Today
BioVie last closing stock price
MetricPriceDate
Last closeUSD 0.252026-10-13
BioVie stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.71%USD 0.282026-10-05
1 month-28.57%USD 0.352026-09-11
3 month-50%USD 0.502026-07-15
Year to date-2.76%USD 0.262025-12-30
1 year-30.98%USD 0.362025-10-13
Since inception-28.57%USD 0.352025-08-08

BioVie Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1.75 (High)

Price

$0.25

Volume

11,886.377

Open

$0.28

Previous Close

$0.25

Daily Range

$0.25 - $0.28

52-Week Range

$0.13 - $0.79

Estimated Earnings Date

Dec 2, 2026

BIVIW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioVie

BioVie Inc. is a clinical-stage biopharmaceutical company focused on developing innovative drug therapies for neurological and neurodegenerative disorders, as well as advanced liver disease. The company is advancing its lead product candidates through critical clinical trials, aiming to address significant unmet medical needs in the United States.

Products and Services
  • BIV201: Phase 3 treatment for liver cirrhosis complications
  • Bezisterim: Phase 3 trial for mild to moderate Alzheimer's disease
  • Investigational therapies for Parkinson's disease and long COVID
Growth Outlook
  • Strong pipeline with multiple candidates in advanced clinical stages
  • Potential market expansion in neurodegenerative disorders
  • Increased focus on partnerships to enhance development capabilities
Financial Highlights
  • Market capitalization of approximately $2.39 million
  • Stock price range between $0.2101 and $0.59 over the past year
  • Low beta of 0.30 indicates lower volatility compared to the market
BioVie Inc. is positioned in the biotechnology sector, with a focus on addressing critical health challenges. The company's lead candidates, BIV201 and Bezisterim, are in pivotal phases of clinical trials, which could significantly impact their market potential. The recent stock price performance reflects a range of investor interest, while the low beta suggests stability in comparison to broader market fluctuations. With a small but dedicated workforce, BioVie Inc. is strategically navigating the complexities of drug development, aiming to bring transformative therapies to patients in need.
AI Generated • Oct 8, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Carson City, NV 89703, US

BIVIW Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

11.89K

Avg. Volume

110.48K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

BioVie Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,803.85-0.00%
^DJIDJI
$51,687.96-0.00%
^IXICNASDAQ
$27,201.84-0.00%
BTCBitcoin
$83,069.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About BIVIW

What is the current price of BioVie?

BioVie is trading at $0.25 per share.

What is the 52-week range for BioVie?

Over the past 52 weeks, BioVie has traded between $0.13 and $0.79.

How much debt does BioVie have?

BioVie total debt is unavailable.

How much cash does BioVie have on hand?

BioVie does not have cash on hand data available.

What is BioVie’s dividend yield?

BioVie does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services